Table 2.

Comparisons of HLA-DRB1 allele frequencies between patients with PM/DM and controls. Values are % unless otherwise specified.

DRB1 Allele	PM	DM	Anti-MDA5–positive PM/DM	Controls	Controls vs Indicated Patients [p, p_c, OR (95% CI)]
DRB1 Allele	PM	DM	Anti-MDA5–positive PM/DM	Controls	PM	DM	Anti-MDA5–positive PM/DM
*01:01	1.4	4.8	6.4	4	ns	ns	ns
*01:02	0.0	1.0	0.0	0.3	ns	ns	ns
*03:01	10.0	9.6	8.5	10.5	ns	ns	ns
*04:01	2.9	8.7	17.0	1.3	ns	ns	1.2 × 10⁻⁹; 3.8 × 10⁻⁸; 16.2 (6.6–39.7)
*04:02	0	0	0	1.3	ns	ns	ns
*04:03	4.3	3.9	4.3	3.3	ns	ns	ns
*04:05	12.9	14.4	14.9	13.3	ns	ns	ns
*04:06	0.0	6.7	10.6	6.3	0.037; ns	ns	ns
*04:07	1.4	1.9	2.1	0	ns	ns	ns
*04:10	0	0	0	0.8	ns	ns	ns
*07:01	14.3	23.1	21.3	12.0	ns	0.004; ns	ns
*08:02	2.9	0.0	0.0	1.3	ns	ns	ns
*08:03	18.6	21.2	14.9	11.8	ns	0.013; ns	ns
*08:09	0	0	0	0.3	ns	ns	ns
*09:01	28.6	19.2	6.4	26.3	ns	ns	0.003; ns
*10:01	7.1	0	0	3	ns	ns	ns
*11:01	14.3	4.8	4.3	12.3	ns	0.03; ns	ns
*11:04	2.9	0	0	0.3	ns	ns	ns
*12:01	5.7	3.9	2.1	8.0	ns	ns	ns
*12:02	12.9	24.0	42.6	19.3	ns	ns	0.0002; 0.008; 3.1 (1.7–5.7)
*12:10	1.4	0	0	0.3	ns	ns	ns
*13:01	7.1	2.9	6.4	2.8	ns	ns	ns
*13:02	5.7	10.6	10.6	7.3	ns	ns	ns
*13:12	0.0	1.9	0	1	ns	ns	ns
*14:03	1.4	0	0	0.3	ns	ns	ns
*14:04	0	0	0	1.5	ns	ns	ns
*14:05	0	1.0	0	5.5	ns	ns	ns
*14:07	0	1.0	0	0.3	ns	ns	ns
*14:54	2.9	0	0	4.3	ns	ns	ns
*15:01	14.3	18.3	17.0	20.8	ns	ns	ns
*15:02	5.7	5.8	4.3	5	ns	ns	ns
*16:01	0	1.0	0	0.3	ns	ns	ns
*16:02	8.6	0	0	7.8	ns	ns	ns

PM: polymyositis; DM: dermatomyositis; anti-MDA5: anti-melanoma differentiation-associated gene 5; p_c: corrected p value; ns: not significant.